Piramal Pharma Limited Reports Q4 and FY26 Financial Results and Future Outlook

Piramal Pharma Limited Reports Q4 and FY26 Financial Results

Piramal Pharma Limited, a leading global player in the pharmaceutical sector, has recently announced its financial results for the fourth quarter and the fiscal year 2026, ending March 31, 2026. The company navigated various challenges over the past year, yet showed resilience in key areas that could pave the way for future growth.

Financial Highlights

In the fourth quarter of 2026, Piramal Pharma recorded operating revenues of ₹2,752 crores, a slight decrease of 0% compared to ₹2,754 crores in the same quarter of 2025. However, for the full fiscal year, revenues totaled ₹8,869 crores, reflecting a 3% decline from the previous year. Segment-wise performance showed varied results, particularly in the Contract Development and Manufacturing Organization (CDMO) segment, which faced a 4% drop in Q4 revenue year-over-year due to destocking and a slowdown in new orders at the start of the year. Conversely, the company’s Critical Healthcare segment (CHG) posted a commendable 7% growth in Q4, aided by increased sales of inhalation anesthetics outside the U.S.

The EBITDA margin was reported at 18%, down from 22% in the previous quarter, attributed to revenue pressures. Despite these hurdles, the company managed to optimize costs, showcasing its commitment to operational excellence.

Strategic Investments

Piramal Pharma invested USD 94 million in fiscal year 2026 across various growth and maintenance projects. Significant expansions in the Lexington and Riverview facilities are currently progressing well, with robust interest from clients signaling future growth potential. The company reported no increase in net debt compared to FY25, indicating prudent financial management amidst fluctuating market conditions.

CEO Insights

Nandini Piramal, the Chairperson, remarked, “2026 has been a transformative year, marked by external disruptions and company-specific challenges. Despite this, we finished on a positive note, with solid momentum across our operations.” She emphasized the resurgence in funding for the biopharmaceutical industry since September 2025, which has started to reflect in improved order bookings within the CDMO segment. The recent acquisition of the Kenalog® brand is expected to strengthen the CHG segment, driving sales growth further.

Key Business Segment Updates

CDMO Segment: The company noted a strong recovery in orders during the latter half of the fiscal year, boosted by a significant 75% increase in biopharmaceutical funding in the U.S. in the second half of 2026. Besides, the global sites experienced rising demand fueled by shifts in geographical preferences from clients.

CHG Segment: Highlights included the finalization of the Kenalog® acquisition process, significantly extending PCL's portfolio within the complex generics space. The inhalation anesthesia segment retained its market leadership with a 47% share, marking a significant improvement from the previous year.

Consumer Healthcare (PCH): The Power Brands segment saw a surge, contributing 52% to PCH sales, growing by 24% year-over-year. E-commerce sales rose by 48%, representing 27% of total PCH sales, indicating a successful strategy of tapping into high-margin channels.

Looking Ahead

As the company gears up for fiscal year 2027, the outlook appears positive with three core segments – CDMO, CHG, and PCH – being well-positioned for growth. The focus will remain on accelerating EBITDA growth and enhancing profit before tax as they leverage their operational efficiencies and strategic investments. Piramal Pharma has clearly laid out its roadmap for the future, aiming for sustained growth despite the headwinds faced in FY26.

Conclusion

Piramal Pharma Limited's recent Q4 and FY26 results reflect a company that, while facing challenges, is also demonstrating agility and strategic foresight. Their commitment to growth, coupled with persistent operational improvements, suggests a forward-looking approach enabling them to adapt and thrive in a dynamic global marketplace.